GeNeuro SA Sustainability Reports

GeNeuro SA is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and autoimmune diseases. It designs monoclonal antibodies to neutralize pathogenic proteins encoded by human endogenous retroviruses.

Sector: Manufacturing

Country: Switzerland

Exchange: Euronext Paris

LEI: 213800FUJCKXO9LK3444

FIGI: BBG00BWQN293

1 reports from 2023 to 2023

• GeNeuro SA 2023 Universal Registration Document Including the Annual Financial Report